Gsa Capital Partners LLP Biotechnology

Gsa Capital Partners LLP

$1.43 Billion
Q2 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
FULC Fulcrum Therapeutics, Inc.	$454M	$224,000 0.02% of portfolio	32,563	Q2 2025 New
ETNB 89bio, Inc.	$682M	$221,000 0.02% of portfolio	22,455	Q2 2025 New
ARQT Arcutis Biotherapeutics, Inc.	$1.12B	$220,000 0.02% of portfolio	15,675	Q2 2025 Reduced 28.44%
ALEC Alector, Inc.	$252M	$211,000 0.01% of portfolio	150,669	Q2 2025 New
CRBU Caribou Biosciences, Inc.	$140M	$210,000 0.01% of portfolio	166,396	Q2 2025 Added 845.16%
DSGN Design Therapeutics, Inc.	$382M	$202,000 0.01% of portfolio	59,975	Q2 2025 Reduced 16.87%
XNCR Xencor Inc	$690M	$183,000 0.01% of portfolio	23,288	Q2 2025 Added 43.43%
EDIT Editas Medicine, Inc.	$242M	$181,000 0.01% of portfolio	82,343	Q2 2025 New
ARVN Arvinas, Inc.	$454M	$176,000 0.01% of portfolio	23,866	Q2 2025 Added 75.45%
ATXS Astria Therapeutics, Inc.	$110M	$166,000 0.01% of portfolio	30,928	Q2 2025 Reduced 53.96%
SNDX Syndax Pharmaceuticals Inc	$880M	$163,000 0.01% of portfolio	17,430	Q2 2025 Reduced 80.03%
ERAS Erasca, Inc.	$258M	$156,000 0.01% of portfolio	123,120	Q2 2025 Reduced 48.42%
HLVX Hille Vax, Inc.	$69.9M	$156,000 0.01% of portfolio	78,466	Q2 2025 Added 233.16%
MRSN Mersana Therapeutics, Inc.	$757M	$140,000 0.01% of portfolio	471,681	Q2 2025 New
DYN Dyne Therapeutics, Inc.	$640M	$133,000 0.01% of portfolio	13,931	Q2 2025 Reduced 85.87%
NAUT Nautilus Biotechnology, Inc.	$99.7M	$128,000 0.01% of portfolio	176,908	Q2 2025 Added 1,313.91%
OMER Omeros Corp	$262M	$114,000 0.01% of portfolio	38,132	Q2 2025 New
TSHA Taysha Gene Therapies, Inc.	$152M	$103,000 0.01% of portfolio	44,690	Q2 2025 New
RCKT Rocket Pharmaceuticals, Inc.	$248M	$91,000 0.01% of portfolio	37,239	Q2 2025 Added 51.18%
CSBR Champions Oncology, Inc.	$86.4M	$77,000 0.01% of portfolio	10,415	Q2 2025 New
IMTX Immatics N.V.	$603M	$68,000 0.0% of portfolio	12,557	Q2 2025 New
PRLD Prelude Therapeutics Inc	$48.7M	$58,000 0.0% of portfolio	71,378	Q2 2025 New
CRTX Cortexyme, Inc.	$70.5M	$56,000 0.0% of portfolio	33,818	Q2 2025 Reduced 7.67%
IFRX Infla Rx N.V.	$57.9M	$46,000 0.0% of portfolio	57,951	Q2 2025 New
ATOS Atossa Therapeutics, Inc.	$109M	$42,000 0.0% of portfolio	51,029	Q2 2025 New
ABOS Acumen Pharmaceuticals, Inc.	$72.1M	$37,000 0.0% of portfolio	32,103	Q2 2025 New
ALXO Alx Oncology Holdings Inc	$71.3M	$34,000 0.0% of portfolio	81,326	Q2 2025 New
GANX Gain Therapeutics, Inc.	$21M	$23,000 0.0% of portfolio	12,756	Q2 2025 New
VXRT Vaxart, Inc.	$45.5M	$22,000 0.0% of portfolio	48,548	Q2 2025 New
CCCC C4 Therapeutics, Inc.	$109M	$16,000 0.0% of portfolio	10,963	Q2 2025 Reduced 75.05%
PLRX Pliant Therapeutics, Inc.	$72M	$16,000 0.0% of portfolio	14,142	Q2 2025 Reduced 59.21%
RANI Rani Therapeutics Holdings, Inc.	$12.2M	$13,000 0.0% of portfolio	25,391	Q2 2025 Reduced 43.11%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.